Evidence map›Paper›PMID 41088219›Full record

ArticleMalaria journal2025

POST introduction evaluation (PIE) of the malaria vaccine introduced in three pilot countries (Ghana, Kenya, and Malawi) in 2021.

Jenny A Walldorf, Gillian F Mayers, Kwame Amponsa-Achiano, Rose Jalang'o, Mike Chisema, Lydia Khalayi, Josephine Njoroge, Adam Haji, Peter O Tweneboah, Emmanuel T Sally and 10 more

Abstract read
In one paragraph

Article in Malaria journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Jenny A WalldorfDepartment of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
Gillian F MayersIndependent Consultant, Echenevex, France.
Kwame Amponsa-AchianoExpanded Programme On Immunization, Public Health Division, Ghana Health Service, Accra, Ghana.
Rose Jalang'oNational Vaccines and Immunization Program, Nairobi, Kenya.
Mike ChisemaMinistry of Health, Lilongwe, Malawi.
Lydia KhalayiNational Vaccines and Immunization Program, Nairobi, Kenya.
Josephine NjorogeWorld Health Organization, Nairobi, Kenya.
Adam HajiWorld Health Organization, Nairobi, Kenya.
Peter O TweneboahWorld Health Organization, Accra, Ghana.
Emmanuel T SallyExpanded Programme On Immunization, Public Health Division, Ghana Health Service, Accra, Ghana.
Donnie MategulaMalawi-Liverpool Wellcome Programme, Blantyre, Malawi.
Brenda MhoneMinistry of Health, Lilongwe, Malawi.
Boston ZimbaWorld Health Organization, Lilongwe, Malawi.
Esther ChirwaWorld Health Organization, Lilongwe, Malawi.
Naziru Tanko MohammedExpanded Programme On Immunization, Public Health Division, Ghana Health Service, Accra, Ghana.
Michael Rockson AdjeiWorld Health Organization, Accra, Ghana.
Jackson SillahTropical and Vector-Borne Diseases Unit, World Health Organization Africa Regional Office, Brazzaville, Congo.
Eliane Pellaux-FurrerDepartment of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
Mgaywa G M D MagafuVaccine-Preventable Diseases Unit, World Health Organization Africa Regional Office, Brazzaville, Congo.
Rafiq N A OkineGlobal Malaria Programme, World Health Organization, Geneva, Switzerland. okiner@who.int.

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundThe World Health Organization (WHO) recommends the use of malaria vaccines for the prevention of Plasmodium falciparum malaria in moderate to high transmission areas, administered in a 4-dose schedule in children from 5 months of age. The vaccine is a ground-breaking new tool to add to the existing package of recommended malaria interventions to reduce malaria morbidity and mortality. Ghana, Kenya, and Malawi were the first countries to introduce the RTS,S/AS01

methodsThe WHO's post-introduction evaluation (PIE) methodology was adapted to evaluate malaria vaccine implementation in each of the three pilot countries at least a year after the vaccine's introduction. Semi-structured questionnaires were used to interview immunization staff at national, sub-national, and health facility levels, supplemented with systematic observations of vaccination sessions and vaccine storage sites. At the health facility, a sample of caregivers of eligible children was also interviewed. Sites were purposively selected to include a range of past immunization coverage and varied demographics among the populations served.

resultsAll three countries successfully introduced the malaria vaccine during the MVIP. Reported malaria vaccine median coverage at least 2 years after the start of the pilot ranged from 69-91% for dose 1, 62-82% for dose 2, to 58-81% for dose 3 by 24-30 months from the start of the pilot. Coverage for dose 4 was lower as fewer children were eligible during the PIE reporting timeframe. Best practices identified during the PIEs included: early involvement of subnational stakeholders; advance updating and distribution of recording and reporting tools to include malaria vaccine; pre-assessment of cold chain capacity and scale-up; investment of time and resources in health worker trainings and refreshers; involvement of community health workers; robust defaulter tracing mechanisms; ensuring community "dialogue" with continuity of advocacy, communication, and social mobilization activities after initial introduction; regular onsite supervisory visits before, during and after introduction; and use of social media for messaging.

conclusionsMalaria vaccine is an important intervention as part of a comprehensive malaria control strategy. Conducting a PIE is useful to identify best practices and lessons learned. New vaccination contacts take time to establish and achieve high coverage as communities become aware of and understand when, why, and how to access the malaria vaccine. The malaria vaccine was successfully introduced as part of the routine childhood immunization programme with strong intersectoral collaboration and planning, involving both immunization and malaria stakeholders, comprehensive training, and social mobilization efforts pre- and post-introduction.

Indexed as

Immunization ProgramsMalaria, FalciparumMalaria VaccinesFemaleGhanaHumansInfantKenyaMalawiPilot ProjectsMalaria VaccinesGhanaKenyaMalaria vaccineMalaria vaccine implementation programmeMalaria vaccine pilot introductionMalawi]New vaccine introductionPost-introduction evaluation

Identifiers

PMID41088219
PMCPMC12522374

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.